Novel ADC therapeutics and precision medicine for cancers
Investors 1
Mentions in press and media 5
| Date | Title | Description |
| 05.08.2026 | Inocras Fuels U.S. Precision Oncology Push with $31M Capital Infusion | Inocras, a San Diego bioinformatics leader, secured $31M in Series B-3 financing, raising its total capital to $100M. This investment fuels rapid U.S. expansion of its CLIA/CAP-certified whole-genome sequencing (WGS) and automated analytics... |
| 05.08.2026 | Inocras Closes $31M in Oversubscribed Series B-3 |
SAN DIEGO, CA, Inocras, a bioinformatics-led company, announced that it has raised $31 million in an oversubscribed Series B-3 financing.
>> Click here for more funding data on Inocras
>> To export Inocras funding data to PDF a... |
| 03.08.2026 | Inocras Closes $31M for Whole-Genome Bioinformatics Platform | What You Should Know
San Diego-based bioinformatics company Inocras Inc. closed an oversubscribed $31M Series B-3 financing round, bringing its total capital raised to approximately $100M.
The funding round was supported by strategic invest... |
| 03.08.2026 | Inocras Closes $31M Series B-3 Financing | Inocras Inc., a San Diego, CA-based bioinformatics-led company leveraging whole-genome data and proprietary analytics to deliver curated insights, raised $31m in Series B-3 financing.
Backers included NDS Corporation, Aimed Bio, IMM Investm... |
| - | AIMEDBIO | “HOME | AIMEDBIO” |
Reviews 0
